NCT04268134View on ClinicalTrials.gov

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions
Breast Cancer
Interventions
DIETARY_SUPPLEMENT

Omega-3 fatty acid supplement

4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).

Trial Locations (1)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT04268134 - Altering Lipids for Tolerance of Aromatase Inhibitor Therapy | Biotech Hunter | Biotech Hunter